Download logo
Hepatitis E is the most common cause of acute viral hepatitis—which causes liver inflammation and damage—leading to approximately 20 million infections and 44,000 deaths per year. Large-scale outbreaks typically occur when water and sanitation are inadequate, such as in refugee and displacement camps, as it is transmitted through fecal contamination of food and water. In addition to being particularly deadly for pregnant women, it also increases the risk of miscarriages and stillbirths.
"The fight against hepatitis E has been long and frustrating," said Dr. Monica Rull, MSF medical director. “Over the last two decades, MSF has been responding to hepatitis E outbreaks in displacement camps, trying to control the disease in challenging conditions, and seeing the devastating impact on extremely vulnerable communities. With the experience of this vaccination campaign, we hope to change the way we tackle hepatitis E in the future.”
In March and April 2022, MSF and South Sudan’s ministry of health jointly carried out the first two rounds of the hepatitis E vaccination campaign in Bentiu. Approximately 25,000 people, including pregnant women, have received the vaccine. A third and final round will be conducted in October 2022.
“Given the successful implementation and the community’s enthusiastic response in the first two rounds, this innovative vaccination campaign can serve as an example and be replicated in similar settings managing hepatitis E outbreaks,” said Dr. John Rumunu, director general for preventive health services at South Sudan’s ministry of health. "I hope the vaccine will help reduce infections and deaths from hepatitis E in Bentiu and beyond."
Bentiu is the largest displaced persons camp in South Sudan, established in 2014 at the height of the civil war. Today, approximately 112,000 people reside there, many having fled recent violence and flooding. MSF has been present in Bentiu since its inception and has seen hepatitis E outbreaks since 2015. The outbreaks are the consequence of appalling living conditions, including a lack of access to adequate water, sanitation, and hygiene.
In 2021, extreme flooding and new influxes of displaced people exacerbated already deplorable living conditions, increasing the spread of waterborne illnesses, including hepatitis E. Since July 2021, MSF has seen in its Bentiu hospital 759 patients with confirmed hepatitis E, 17 of whom died.
The only available hepatitis E vaccine, Hecolin, has been shown in clinical trials to be highly effective at preventing disease, and the World Health Organization (WHO) has recommended that it be considered for use in outbreak responses since 2015. However, until now, it has only been used on an individual basis in China, where it is licensed and used to vaccinate travelers. The vaccination campaign in Bentiu is the first time it has been used in response to a public health emergency.
"This is a significant milestone in global efforts to tackle hepatitis E," said Melanie Marti, immunization, vaccines, and biologicals medical officer at the WHO. "It is the first time a vaccine has been used to combat the effects of this potentially devastating disease. This is despite the fact that the vaccine has been licensed for over a decade, and it has been WHO policy to use it in outbreak settings since 2015. At the WHO, we strongly encourage all countries experiencing an outbreak to use the vaccine against hepatitis E, including in pregnant women."
The success of the Bentiu vaccination campaign shows that it is possible to use the vaccine for outbreak response, even in difficult conditions. South Sudan’s ministry of health and MSF are monitoring and reporting on the results of the vaccination campaign. While other outbreak control measures are also necessary—including improving water and sanitation services—health officials believe this vaccination campaign is an important step toward reducing the burden of hepatitis E in the future. MSF hopes the campaign will encourage other countries to use the vaccine as part of measures to control outbreaks of hepatitis E.
Distributed by APO Group on behalf of Médecins sans frontières (MSF).
This website uses cookies.